Discovery and characterization of inhibitors of human palmitoyl acyltransferases

Charles E. Ducker, Lindsay K. Griffel, Ryan A. Smith, Staci N. Keller, Yan Zhuang, Zuping Xia, John D. Diller, Charles D. Smith

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

The covalent attachment of palmitate to specific proteins by the action of palmitoyl acyltransferases (PAT) plays critical roles in the biological activities of several oncoproteins. Two PAT activities are expressed by human cells: type 1 PATs that modify the farnesyl-dependent palmitoylation motif found in H- and N-Ras, and type 2 PATs that modify the myristoyl-dependent palmitoylation motif found in the Src family of tyrosine kinases. We have previously shown that the type 1 PAT HIP14 causes cellular transformation. In the current study, we show that mRNA encoding HIP14 is up-regulated in a number of types of human tumors. To assess the potential of HIP14 and other PATs as targets for new anticancer drugs, we developed three cell-based assays suitable for high-throughput screening to identify inhibitors of these enzymes. Using these screens, five chemotypes, with activity toward either type 1 or type 2 PAT activity, were identified. The activity of the hits were confirmed using assays that quantify the in vitro inhibition of PAT activity, as well as a cell-based assay that determines the abilities of the compounds to prevent the localization of palmitoylated green fluorescent proteins to the plasma membrane. Representative compounds from each chemotype showed broad antiproliferative activity toward a panel of human tumor cell lines and inhibited the growth of tumors in vivo. Together, these data show that PATs, and HIP14 in particular, are interesting new targets for anticancer compounds, and that small molecules with such activity can be identified by high-throughput screening.

Original languageEnglish (US)
Pages (from-to)1647-1659
Number of pages13
JournalMolecular cancer therapeutics
Volume5
Issue number7
DOIs
StatePublished - Jul 1 2006

Fingerprint

Acyltransferases
Lipoylation
High-Throughput Screening Assays
src-Family Kinases
Palmitates
Oncogene Proteins
Enzyme Inhibitors
Green Fluorescent Proteins
Tumor Cell Line
Human Activities
Neoplasms
Cell Membrane
Messenger RNA
Growth
Pharmaceutical Preparations
Proteins

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Ducker, C. E., Griffel, L. K., Smith, R. A., Keller, S. N., Zhuang, Y., Xia, Z., ... Smith, C. D. (2006). Discovery and characterization of inhibitors of human palmitoyl acyltransferases. Molecular cancer therapeutics, 5(7), 1647-1659. https://doi.org/10.1158/1535-7163.MCT-06-0114
Ducker, Charles E. ; Griffel, Lindsay K. ; Smith, Ryan A. ; Keller, Staci N. ; Zhuang, Yan ; Xia, Zuping ; Diller, John D. ; Smith, Charles D. / Discovery and characterization of inhibitors of human palmitoyl acyltransferases. In: Molecular cancer therapeutics. 2006 ; Vol. 5, No. 7. pp. 1647-1659.
@article{d166851ca6e94db1b2f0ad0f0620f82b,
title = "Discovery and characterization of inhibitors of human palmitoyl acyltransferases",
abstract = "The covalent attachment of palmitate to specific proteins by the action of palmitoyl acyltransferases (PAT) plays critical roles in the biological activities of several oncoproteins. Two PAT activities are expressed by human cells: type 1 PATs that modify the farnesyl-dependent palmitoylation motif found in H- and N-Ras, and type 2 PATs that modify the myristoyl-dependent palmitoylation motif found in the Src family of tyrosine kinases. We have previously shown that the type 1 PAT HIP14 causes cellular transformation. In the current study, we show that mRNA encoding HIP14 is up-regulated in a number of types of human tumors. To assess the potential of HIP14 and other PATs as targets for new anticancer drugs, we developed three cell-based assays suitable for high-throughput screening to identify inhibitors of these enzymes. Using these screens, five chemotypes, with activity toward either type 1 or type 2 PAT activity, were identified. The activity of the hits were confirmed using assays that quantify the in vitro inhibition of PAT activity, as well as a cell-based assay that determines the abilities of the compounds to prevent the localization of palmitoylated green fluorescent proteins to the plasma membrane. Representative compounds from each chemotype showed broad antiproliferative activity toward a panel of human tumor cell lines and inhibited the growth of tumors in vivo. Together, these data show that PATs, and HIP14 in particular, are interesting new targets for anticancer compounds, and that small molecules with such activity can be identified by high-throughput screening.",
author = "Ducker, {Charles E.} and Griffel, {Lindsay K.} and Smith, {Ryan A.} and Keller, {Staci N.} and Yan Zhuang and Zuping Xia and Diller, {John D.} and Smith, {Charles D.}",
year = "2006",
month = "7",
day = "1",
doi = "10.1158/1535-7163.MCT-06-0114",
language = "English (US)",
volume = "5",
pages = "1647--1659",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

Ducker, CE, Griffel, LK, Smith, RA, Keller, SN, Zhuang, Y, Xia, Z, Diller, JD & Smith, CD 2006, 'Discovery and characterization of inhibitors of human palmitoyl acyltransferases', Molecular cancer therapeutics, vol. 5, no. 7, pp. 1647-1659. https://doi.org/10.1158/1535-7163.MCT-06-0114

Discovery and characterization of inhibitors of human palmitoyl acyltransferases. / Ducker, Charles E.; Griffel, Lindsay K.; Smith, Ryan A.; Keller, Staci N.; Zhuang, Yan; Xia, Zuping; Diller, John D.; Smith, Charles D.

In: Molecular cancer therapeutics, Vol. 5, No. 7, 01.07.2006, p. 1647-1659.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Discovery and characterization of inhibitors of human palmitoyl acyltransferases

AU - Ducker, Charles E.

AU - Griffel, Lindsay K.

AU - Smith, Ryan A.

AU - Keller, Staci N.

AU - Zhuang, Yan

AU - Xia, Zuping

AU - Diller, John D.

AU - Smith, Charles D.

PY - 2006/7/1

Y1 - 2006/7/1

N2 - The covalent attachment of palmitate to specific proteins by the action of palmitoyl acyltransferases (PAT) plays critical roles in the biological activities of several oncoproteins. Two PAT activities are expressed by human cells: type 1 PATs that modify the farnesyl-dependent palmitoylation motif found in H- and N-Ras, and type 2 PATs that modify the myristoyl-dependent palmitoylation motif found in the Src family of tyrosine kinases. We have previously shown that the type 1 PAT HIP14 causes cellular transformation. In the current study, we show that mRNA encoding HIP14 is up-regulated in a number of types of human tumors. To assess the potential of HIP14 and other PATs as targets for new anticancer drugs, we developed three cell-based assays suitable for high-throughput screening to identify inhibitors of these enzymes. Using these screens, five chemotypes, with activity toward either type 1 or type 2 PAT activity, were identified. The activity of the hits were confirmed using assays that quantify the in vitro inhibition of PAT activity, as well as a cell-based assay that determines the abilities of the compounds to prevent the localization of palmitoylated green fluorescent proteins to the plasma membrane. Representative compounds from each chemotype showed broad antiproliferative activity toward a panel of human tumor cell lines and inhibited the growth of tumors in vivo. Together, these data show that PATs, and HIP14 in particular, are interesting new targets for anticancer compounds, and that small molecules with such activity can be identified by high-throughput screening.

AB - The covalent attachment of palmitate to specific proteins by the action of palmitoyl acyltransferases (PAT) plays critical roles in the biological activities of several oncoproteins. Two PAT activities are expressed by human cells: type 1 PATs that modify the farnesyl-dependent palmitoylation motif found in H- and N-Ras, and type 2 PATs that modify the myristoyl-dependent palmitoylation motif found in the Src family of tyrosine kinases. We have previously shown that the type 1 PAT HIP14 causes cellular transformation. In the current study, we show that mRNA encoding HIP14 is up-regulated in a number of types of human tumors. To assess the potential of HIP14 and other PATs as targets for new anticancer drugs, we developed three cell-based assays suitable for high-throughput screening to identify inhibitors of these enzymes. Using these screens, five chemotypes, with activity toward either type 1 or type 2 PAT activity, were identified. The activity of the hits were confirmed using assays that quantify the in vitro inhibition of PAT activity, as well as a cell-based assay that determines the abilities of the compounds to prevent the localization of palmitoylated green fluorescent proteins to the plasma membrane. Representative compounds from each chemotype showed broad antiproliferative activity toward a panel of human tumor cell lines and inhibited the growth of tumors in vivo. Together, these data show that PATs, and HIP14 in particular, are interesting new targets for anticancer compounds, and that small molecules with such activity can be identified by high-throughput screening.

UR - http://www.scopus.com/inward/record.url?scp=33748299575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748299575&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-06-0114

DO - 10.1158/1535-7163.MCT-06-0114

M3 - Article

C2 - 16891450

AN - SCOPUS:33748299575

VL - 5

SP - 1647

EP - 1659

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 7

ER -